Milestones

2007Q4 ELR105813 shows activity against human tumor xenograft in vivo.

elara's pipeline

elara pipeline

Target Classes & Opportunities

Hypoxia Signaling Antagonists
The signaling pathways activated by low oxygen availability, or hypoxia, allow cell adaptation and survival in the hypoxic environment including angiogenesis. The hypoxic response in tumors mediated by the Hypoxia Inducible Factor (HIF) is associated with resistance to radiotherapy and poor clinical outcome.

Deprivation of blood supply to tumors has been unequivocally validated as a therapeutic strategy in oncology. Anti-HIF drugs work by preventing development and growth of new tumor vessels through suppression of the hypoxic response. However, these drugs do not affect established tumor vasculature creating the opportunity for enhanced therapeutic benefits with the use of HIF inhibitors.

ELARA has built up a portfolio of proprietary highly potent HIF Signaling pathway inhibitors. Examples from the chemotypes show excellent in vitro activity against a diverse set of tumor cell lines and show superior pharmacokinetic and toxicity profile in vivo. Our lead candidate is expected to enter pre-clinical development in Q1 2009 with first in man studies initiated in Q1 2010.

Allosteric Kinase Inhibitors: Aurora
Ground breaking research from EMBL research groups enabled the identification of a novel allosteric regulatory site of Aurora A kinase that is essential for proper protein function. In our Aurora program, we established a proprietary portfolio of allosteric inhibitor chemotypes

aurora